ELacestrant

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 104 publications

Imlunestrant (Inluriyo) for advanced breast cancer.

Imlunestrant (Inluriyo) for advanced breast cancer.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Elacestrant in metastatic breast cancer: current advancements and future perspectives.

Journal: Expert review of anticancer therapy

Published: December 29, 2025

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Real-World Evidence for 10 Oncology Drugs Approved in the last 5 years: A Comprehensive Narrative Synthesis.

Journal: Critical reviews in oncology/hematology

Published: December 08, 2025

Characterization of In Vitro Metabolic Profiles of Elacestrant in Rat and Human Liver Microsomes Using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS.

Characterization of In Vitro Metabolic Profiles of Elacestrant in Rat and Human Liver Microsomes Using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS.

Journal: Biomedical chromatography : BMC

Published: December 02, 2025

Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer.

Protacs Targeting ERα in the Effective Management of Endocrinal Resistance Breast Cancer.

Journal: Archiv der Pharmazie

Published: September 11, 2025

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 13, 2025

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 13, 2025

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.

Journal: EClinicalMedicine

Published: July 15, 2025

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS).

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS).

Journal: Scientific reports

Published: July 09, 2025

A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents.

A Computational Strategy to Identify Hub Genes in Pathway Analysis of Gamma Tocotrienol-treated MCF-7 Cells and Molecular Docking Study Using Selected Phytochemicals as Therapeutic Agents.

Journal: Current medicinal chemistry

Published: June 28, 2025

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance.

PML1-Mediated Feedforward Loop Through PI3K and MAPK Axes Drives Endocrine Resistance.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2025

Showing 1-12 of 104

Last Updated: 04/28/2026